Skip to main content
SpringerLink
Log in

Thrombotic Microangiopathy in the Adolescent Female

  • Chapter
  • First Online:
Hematology in the Adolescent Female

  • 388 Accesses

Abstract

Thrombotic microangiopathies (TMAs) are life-threatening hematologic disorders that share signs and symptoms present in other hematologic disorders, menorrhagia, and pregnancy. For clinicians caring for adolescent females, it is imperative to keep these disorders in the differential diagnosis when approaching a young woman with hemolytic anemia, thrombocytopenia, or kidney dysfunction. Timely diagnosis and initiation of appropriate therapy, especially in the case of thrombotic thrombocytopenic purpura, can help prevent the morbidity and mortality that is associated with these disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347(8):589–600.

    CAS  PubMed  Google Scholar 

  2. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lammle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood. 1997;89(9):3097–103.

    CAS  PubMed  Google Scholar 

  3. Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc N Y Pathol Soc. 1924;24:21–4.

    Google Scholar 

  4. Furlan M, Lammle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Best Pract Res Clin Haematol. 2001;14(2):437–54.

    CAS  PubMed  Google Scholar 

  5. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339(22):1578–84.

    CAS  PubMed  Google Scholar 

  6. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339(22):1585–94.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Fujimura Y, Matsumoto M, Isonishi A, Yagi H, Kokame K, Soejima K, et al. Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan. J Thromb Haemost. 2011;9 Suppl 1:283–301.

    CAS  PubMed  Google Scholar 

  8. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413(6855):488–94.

    CAS  PubMed  Google Scholar 

  9. George JN. Congenital thrombotic thrombocytopenic purpura: lessons for recognition and management of rare syndromes. Pediatr Blood Cancer. 2008;50(5):947–8.

    PubMed  Google Scholar 

  10. Scully M, Hunt BJ, Benjamin S, Liesner R, Rose P, Peyvandi F, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158(3):323–35.

    PubMed  Google Scholar 

  11. George JN. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood. 2010;116(20):4060–9.

    CAS  PubMed  Google Scholar 

  12. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325(6):393–7.

    CAS  PubMed  Google Scholar 

  13. George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371(7):654–66.

    CAS  PubMed  Google Scholar 

  14. Moatti-Cohen M, Garrec C, Wolf M, Boisseau P, Galicier L, Azoulay E, et al. Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood. 2012;119(24):5888–97.

    CAS  PubMed  Google Scholar 

  15. von Auer C, von Krogh AS, Kremer Hovinga JA, Lammle B. Current insights into thrombotic microangiopathies: thrombotic thrombocytopenic purpura and pregnancy. Thromb Res. 2015;135 Suppl 1:S30–3.

    Google Scholar 

  16. Scully M, Thomas M, Underwood M, Watson H, Langley K, Camilleri RS, et al. Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes. Blood. 2014;124(2):211–9.

    CAS  PubMed  Google Scholar 

  17. Epperla N, Hemauer K, Friedman KD, George JN, Foy P. Congenital thrombotic thrombocytopenic purpura related to a novel mutation in ADAMTS13 gene and management during pregnancy. Am J Hematol. 2016;91(6):644–6.

    PubMed  Google Scholar 

  18. von Krogh AS, Quist-Paulsen P, Waage A, Langseth OO, Thorstensen K, Brudevold R, et al. High prevalence of hereditary thrombotic thrombocytopenic purpura in central Norway: from clinical observation to evidence. J Thromb Haemost. 2016;14(1):73–82.

    Google Scholar 

  19. Fuchs WE, George JN, Dotin LN, Sears DA. Thrombotic thrombocytopenic purpura. Occurrence two years apart during late pregnancy in two sisters. JAMA. 1976;235(19):2126–7.

    CAS  PubMed  Google Scholar 

  20. George JN, Charania RS. Evaluation of patients with microangiopathic hemolytic anemia and thrombocytopenia. Semin Thromb Hemost. 2013;39(2):153–60.

    PubMed  Google Scholar 

  21. George JN. Measuring ADAMTS13 activity in patients with suspected thrombotic thrombocytopenic purpura: when, how, and why? Transfusion. 2015;55(1):11–3.

    PubMed  PubMed Central  Google Scholar 

  22. Fremeaux-Bacchi V, Dragon-Durey MA, Blouin J, Vigneau C, Kuypers D, Boudailliez B, et al. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet. 2004;41(6):e84.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Richards A, Kemp EJ, Liszewski MK, Goodship JA, Lampe AK, Decorte R, et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A. 2003;100(22):12966–71.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, Carreras L, Arranz EA, Garrido CA, et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A. 2007;104(1):240–5.

    CAS  PubMed  Google Scholar 

  25. Ying L, Katz Y, Schlesinger M, Carmi R, Shalev H, Haider N, et al. Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome. Am J Hum Genet. 1999;65(6):1538–46.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Dragon-Durey MA, Loirat C, Cloarec S, Macher MA, Blouin J, Nivet H, et al. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2005;16(2):555–63.

    CAS  PubMed  Google Scholar 

  27. Sperati CJ, Moliterno AR. Thrombotic microangiopathy: focus on atypical hemolytic uremic syndrome. Hematol Oncol Clin North Am. 2015;29(3):541–59.

    PubMed  Google Scholar 

  28. Greenbaum LA. Atypical hemolytic uremic syndrome. Adv Pediatr. 2014;61(1):335–56.

    PubMed  Google Scholar 

  29. Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Fremeaux-Bacchi V, Kavanagh D, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int. 2017;91(3):539–51.

    CAS  PubMed  Google Scholar 

  30. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169–81.

    CAS  PubMed  Google Scholar 

  31. Fakhouri F, Zuber J, Fremeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet (London, England). 2017;390(10095):681–96.

    Google Scholar 

  32. Gottschall JL, Neahring B, McFarland JG, Wu GG, Weitekamp LA, Aster RH. Quinine-induced immune thrombocytopenia with hemolytic uremic syndrome: clinical and serological findings in nine patients and review of literature. Am J Hematol. 1994;47(4):283–9.

    CAS  PubMed  Google Scholar 

  33. Sartelet H, Toupance O, Lorenzato M, Fadel F, Noel LH, Lagonotte E, et al. Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. Am J Transplant. 2005;5(10):2441–7.

    PubMed  Google Scholar 

  34. Rabadi SJ, Khandekar JD, Miller HJ. Mitomycin-induced hemolytic uremic syndrome: case presentation and review of literature. Cancer Treat Rep. 1982;66(5):1244–7.

    CAS  PubMed  Google Scholar 

  35. Moake JL, Byrnes JJ. Thrombotic microangiopathies associated with drugs and bone marrow transplantation. Hematol Oncol Clin North Am. 1996;10(2):485–97.

    CAS  PubMed  Google Scholar 

  36. Ambruzs JM, Serrell PB, Rahim N, Larsen CP. Thrombotic microangiopathy and acute kidney injury associated with intravenous abuse of an oral extended-release formulation of oxymorphone hydrochloride: kidney biopsy findings and report of 3 cases. Am J Kidney Dis. 2014;63(6):1022–6.

    PubMed  Google Scholar 

  37. Lammle B. Opana ER-induced thrombotic microangiopathy. Blood. 2017;129(7):808–9.

    CAS  PubMed  Google Scholar 

  38. Koenig JC, Rutsch F, Bockmeyer C, Baumgartner M, Beck BB, Kranz B, et al. Nephrotic syndrome and thrombotic microangiopathy caused by cobalamin C deficiency. Pediatr Nephrol (Berlin, Germany). 2015;30(7):1203–6.

    Google Scholar 

  39. Lemaire M, Fremeaux-Bacchi V, Schaefer F, Choi M, Tang WH, Le Quintrec M, et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet. 2013;45(5):531–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Delvaeye M, Noris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G, et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(4):345–57.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Ridolfi RL, Bell WR. Thrombotic thrombocytopenic purpura. Report of 25 cases and review of the literature. Medicine (Baltimore). 1981;60(6):413–28.

    CAS  Google Scholar 

  42. George JN. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med. 2006;354(18):1927–35.

    CAS  PubMed  Google Scholar 

  43. Scully M, Goodship T. How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome. Br J Haematol. 2014;164(6):759–66.

    PubMed  PubMed Central  Google Scholar 

  44. Allford SL, Hunt BJ, Rose P, Machin SJ. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol. 2003;120(4):556–73.

    PubMed  Google Scholar 

  45. Wu N, Liu J, Yang S, Kellett ET, Cataland SR, Li H, et al. Diagnostic and prognostic values of ADAMTS13 activity measured during daily plasma exchange therapy in patients with acquired thrombotic thrombocytopenic purpura. Transfusion. 2015;55(1):18–24.

    CAS  PubMed  Google Scholar 

  46. Fontana S, Kremer Hovinga JA, Studt JD, Alberio L, Lammle B, Taleghani BM. Plasma therapy in thrombotic thrombocytopenic purpura: review of the literature and the Bern experience in a subgroup of patients with severe acquired ADAMTS-13 deficiency. Semin Hematol. 2004;41(1):48–59.

    CAS  PubMed  Google Scholar 

  47. Sadler JE, Moake JL, Miyata T, George JN. Recent advances in thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program. 2004:407–23.

    Google Scholar 

  48. Bresin E, Gastoldi S, Daina E, Belotti D, Pogliani E, Perseghin P, et al. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. Thromb Haemost. 2009;101(2):233–8.

    CAS  PubMed  Google Scholar 

  49. Scully M, McDonald V, Cavenagh J, Hunt BJ, Longair I, Cohen H, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood. 2011;118(7):1746–53.

    CAS  PubMed  Google Scholar 

  50. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol. 2003;14(4):520–35.

    CAS  PubMed  Google Scholar 

  51. Tsai HM. Current concepts in thrombotic thrombocytopenic purpura. Annu Rev Med. 2006;57:419–36.

    CAS  PubMed  PubMed Central  Google Scholar 

  52. Ahmad HN, Thomas-Dewing RR, Hunt BJ. Mycophenolate mofetil in a case of relapsed, refractory thrombotic thrombocytopenic purpura. Eur J Haematol. 2007;78(5):449–52.

    CAS  PubMed  Google Scholar 

  53. Shortt J, Oh DH, Opat SS. ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. N Engl J Med. 2013;368(1):90–2.

    CAS  PubMed  Google Scholar 

  54. Eskazan AE. Bortezomib therapy in patients with relapsed/refractory acquired thrombotic thrombocytopenic purpura. Ann Hematol. 2016;95(11):1751–6.

    CAS  PubMed  Google Scholar 

  55. Fontana S, Kremer Hovinga JA, Lammle B, Mansouri TB. Treatment of thrombotic thrombocytopenic purpura. Vox Sang. 2006;90(4):245–54.

    CAS  PubMed  Google Scholar 

  56. Jamme M, Rondeau E. The PLASMIC score for thrombotic thrombocytopenic purpura. Lancet Haemat. 2017;4(4):e148–e9.

    Google Scholar 

  57. Bendapudi PK, Hurwitz S, Fry A, Marques MB, Waldo SW, Li A, et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol. 2017;4(4):e157–e64.

    PubMed  Google Scholar 

  58. Cofiell R, Kukreja A, Bedard K, Yan Y, Mickle AP, Ogawa M, et al. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood. 2015;125(21):3253–62.

    CAS  PubMed  PubMed Central  Google Scholar 

  59. Olson SR, Lu E, Sulpizio E, Shatzel JJ, Rueda JF, DeLoughery TG. When to stop eculizumab in complement-mediated thrombotic microangiopathies. Am J Nephrol. 2018;48(2):96–107.

    CAS  PubMed  Google Scholar 

  60. Ardissino G, Testa S, Possenti I, Tel F, Paglialonga F, Salardi S, et al. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis. 2014;64(4):633–7.

    CAS  PubMed  Google Scholar 

  61. Schoettler M, Lehmann L, Li A, Ma C, Duncan C. Thrombotic microangiopathy following pediatric autologous hematopoietic cell transplantation: a report of significant end-organ dysfunction in eculizumab-treated survivors. Biol Blood Marrow Transplant. 2019;25(5):e163–e8.

    PubMed  PubMed Central  Google Scholar 

  62. Ardissino G, Tel F, Sgarbanti M, Cresseri D, Giussani A, Griffini S, et al. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update. Pediatr Nephrol (Berlin, Germany). 2018;33(3):457–61.

    Google Scholar 

  63. Jodele S, Fukuda T, Vinks A, Mizuno K, Laskin BL, Goebel J, et al. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant. 2014;20(4):518–25.

    CAS  PubMed  Google Scholar 

  64. Parker C. Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet (London, England). 2009;373(9665):759–67.

    CAS  Google Scholar 

  65. Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5(10):1844–59.

    CAS  PubMed  PubMed Central  Google Scholar 

  66. Jodele S, Laskin BL, Goebel J, Khoury JC, Pinkard SL, Carey PM, et al. Does early initiation of therapeutic plasma exchange improve outcome in pediatric stem cell transplant-associated thrombotic microangiopathy? Transfusion. 2013;53(3):661–7.

    CAS  PubMed  Google Scholar 

  67. Boyer O, Balzamo E, Charbit M, Biebuyck-Gouge N, Salomon R, Dragon-Durey MA, et al. Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies. Am J Kidney Dis. 2010;55(5):923–7.

    PubMed  Google Scholar 

  68. Sana G, Dragon-Durey MA, Charbit M, Bouchireb K, Rousset-Rouviere C, Berard E, et al. Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses. Pediatr Nephrol (Berlin, Germany). 2014;29(1):75–83.

    Google Scholar 

  69. Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol (Berlin, Germany). 2016;31(1):15–39.

    Google Scholar 

  70. Porta C, Caporali R, Montecucco C. Thrombotic thrombocytopenic purpura and autoimmunity: a tale of shadows and suspects. Haematologica. 1999;84(3):260–9.

    CAS  PubMed  Google Scholar 

  71. Muscal E, Edwards RM, Kearney DL, Hicks JM, Myones BL, Teruya J. Thrombotic microangiopathic hemolytic anemia with reduction of ADAMTS13 activity: initial manifestation of childhood-onset systemic lupus erythematosus. Am J Clin Pathol. 2011;135(3):406–16.

    PubMed  Google Scholar 

  72. Kremer Hovinga JA, Vesely SK, Terrell DR, Lammle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;115(8):1500–11; quiz 662.

    PubMed  Google Scholar 

  73. Vesely SK, George JN, Lammle B, Studt JD, Alberio L, El-Harake MA, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003;102(1):60–8.

    CAS  PubMed  Google Scholar 

  74. Sadler JE. Pathophysiology of thrombotic thrombocytopenic purpura. Blood. 2017;130(10):1181–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  75. Lewis QF, Lanneau MS, Mathias SD, Terrell DR, Vesely SK, George JN. Long-term deficits in health-related quality of life after recovery from thrombotic thrombocytopenic purpura. Transfusion. 2009;49(1):118–24.

    PubMed  Google Scholar 

  76. Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011;6:60.

    PubMed  PubMed Central  Google Scholar 

  77. Uderzo C, Bonanomi S, Busca A, Renoldi M, Ferrari P, Iacobelli M, et al. Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Transplantation. 2006;82(5):638–44.

    PubMed  Google Scholar 

  78. Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaime F, Dragon-Durey MA, Ngo S, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8(4):554–62.

    CAS  PubMed  PubMed Central  Google Scholar 

  79. Sayani FA, Abrams CS. How I treat refractory thrombotic thrombocytopenic purpura. Blood. 2015;125(25):3860–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  80. Schiviz A, Wuersch K, Piskernik C, Dietrich B, Hoellriegl W, Rottensteiner H, et al. A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13. Blood. 2012;119(25):6128–35.

    CAS  PubMed  Google Scholar 

  81. Aledort LM, Singleton TC, Ulsh PJ. Treatment of congenital thrombotic thrombocytopenia Purpura: a new paradigm. J Pediatr Hematol Oncol. 2017;39(7):524–7.

    PubMed  Google Scholar 

  82. Scully M, Cataland SR, Peyvandi F, Coppo P, Knobl P, Kremer Hovinga JA, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic Purpura. N Engl J Med. 2019;380(4):335–46.

    CAS  PubMed  Google Scholar 

  83. Harris CL, Pouw RB, Kavanagh D, Sun R, Ricklin D. Developments in anti-complement therapy; from disease to clinical trial. Mol Immunol. 2018;102:89–119.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine, Texas Children’s Hospital, Houston, TX, USA

    Clay T. Cohen & Sarah E. Sartain

  2. Pediatric Hematology, Mississippi Center for Advanced Medicine, Madison, MS, USA

    Tammuella Chrisentery Singleton

Authors
  1. Clay T. Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tammuella Chrisentery Singleton
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sarah E. Sartain
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Clay T. Cohen .

Editor information

Editors and Affiliations

  1. Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA

    Lakshmi V. Srivaths

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Cohen, C.T., Singleton, T.C., Sartain, S.E. (2020). Thrombotic Microangiopathy in the Adolescent Female. In: Srivaths, L. (eds) Hematology in the Adolescent Female. Springer, Cham. https://doi.org/10.1007/978-3-030-48446-0_25

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-48446-0_25

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-48445-3

  • Online ISBN: 978-3-030-48446-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation